Abstract
Small non-protein coding RNAs are involved in pathways that control the genome at the level of chromatin. In Schizosaccharomyces pombe, small interfering RNAs (siRNAs) are required for the faithful propagation of heterochromatin that is found at peri-centromeric repeats. In contrast to repetitive DNA, protein-coding genes are refractory to siRNA-mediated heterochromatin formation, unless siRNAs are expressed in mutant cells. Here we report the identification of 20 novel mutant alleles that enable de novo formation of heterochromatin at a euchromatic protein-coding gene by using trans-acting siRNAs as triggers. For example, a single amino acid substitution in the pre-mRNA cleavage factor Yth1 enables siRNAs to trigger silent chromatin formation with unparalleled efficiency. Our results are consistent with a kinetic nascent transcript processing model for the inhibition of small-RNA-directed de novo formation of heterochromatin and lay a foundation for further mechanistic dissection of cellular activities that counteract epigenetic gene silencing.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alleles
-
Amino Acid Substitution
-
Centromere / chemistry
-
Centromere / metabolism
-
Chromatin Assembly and Disassembly
-
Gene Expression Profiling
-
Gene Expression Regulation, Fungal*
-
Gene Silencing*
-
Heterochromatin / chemistry
-
Heterochromatin / metabolism
-
Kinetics
-
Models, Genetic
-
Molecular Sequence Annotation
-
Mutation
-
RNA, Messenger / genetics*
-
RNA, Messenger / metabolism
-
RNA, Small Interfering / genetics*
-
RNA, Small Interfering / metabolism
-
Schizosaccharomyces / genetics*
-
Schizosaccharomyces / metabolism
-
mRNA Cleavage and Polyadenylation Factors / genetics*
-
mRNA Cleavage and Polyadenylation Factors / metabolism
Substances
-
Heterochromatin
-
RNA, Messenger
-
RNA, Small Interfering
-
mRNA Cleavage and Polyadenylation Factors
Grants and funding
This work has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 681213 - REpiReg) (M.B.) and the Novartis Research Foundation (M.B.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.